{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:29:40Z","timestamp":1790508580363,"version":"4.1.0"},"reference-count":97,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.apsb.2024.07.025","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T07:46:55Z","timestamp":1722584815000},"page":"35-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Drug discovery targeting thyroid hormone receptor \u03b2 (THR\u03b2) for the treatment of liver diseases and other medical indications"],"prefix":"10.1016","volume":"15","author":[{"given":"Kean","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feiyang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3685-6268","authenticated-orcid":false,"given":"Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2024.07.025_bib1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1146\/annurev.physiol.62.1.439","article-title":"The mechanism of action of thyroid hormones","volume":"62","author":"Zhang","year":"2000","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.apsb.2024.07.025_bib2","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1172\/JCI60047","article-title":"Mechanisms of thyroid hormone action","volume":"122","author":"Brent","year":"2012","journal-title":"J Clin Investig"},{"key":"10.1016\/j.apsb.2024.07.025_bib3","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1152\/physrev.00030.2013","article-title":"Thyroid hormone regulation of metabolism","volume":"94","author":"Mullur","year":"2014","journal-title":"Physiol Rev"},{"key":"10.1016\/j.apsb.2024.07.025_bib4","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1126\/science.3283939","article-title":"The steroid and thyroid hormone receptor superfamily","volume":"240","author":"Evans","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.apsb.2024.07.025_bib5","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1210\/er.2009-0010","article-title":"The role of liver-derived insulin-like growth factor-I","volume":"30","author":"Ohlsson","year":"2009","journal-title":"Endocr Rev"},{"key":"10.1016\/j.apsb.2024.07.025_bib6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1006\/dbio.2000.9975","article-title":"Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth","volume":"229","author":"Lupu","year":"2001","journal-title":"Dev Biol"},{"key":"10.1016\/j.apsb.2024.07.025_bib7","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/nrendo.2013.238","article-title":"Thyroid hormones and skeletal muscle-new insights and potential implications","volume":"10","author":"Salvatore","year":"2014","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.apsb.2024.07.025_bib8","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1210\/endo.137.3.8603571","article-title":"Cell-specific effects of thyroid hormone on RC3\/neurogranin expression in rat brain","volume":"137","author":"Iniguez","year":"1996","journal-title":"Endocrinology"},{"key":"10.1016\/j.apsb.2024.07.025_bib9","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.bbalip.2013.01.009","article-title":"UCP1 mRNA does not produce heat","volume":"1831","author":"Nedergaard","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.apsb.2024.07.025_bib10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-201X.2004.01380.x","article-title":"Mechanisms regulating GLUT4 glucose transporter expression and glucose transport in skeletal muscle","volume":"183","author":"Zorzano","year":"2005","journal-title":"Acta Physiol Scand"},{"key":"10.1016\/j.apsb.2024.07.025_bib11","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/j.1365-2826.2004.01243.x","article-title":"Timing of thyroid hormone action in the developing brain: clinical observations and experimental findings","volume":"16","author":"Zoeller","year":"2004","journal-title":"J Neuroendocrinol"},{"key":"10.1016\/j.apsb.2024.07.025_bib12","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nrendo.2014.143","article-title":"Thyroid hormone receptors and resistance to thyroid hormone disorders","volume":"10","author":"Ortiga-Carvalho","year":"2014","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.apsb.2024.07.025_bib13","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10741-008-9125-7","article-title":"Cardiac hypertrophy and thyroid hormone signaling","volume":"15","author":"Dillmann","year":"2010","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.apsb.2024.07.025_bib14","doi-asserted-by":"crossref","first-page":"4945","DOI":"10.1210\/endo.139.12.6412","article-title":"Thyroid hormone action on liver, heart, and energy expenditure in thyroid hormone receptor beta-deficient mice","volume":"139","author":"Weiss","year":"1998","journal-title":"Endocrinology"},{"key":"10.1016\/j.apsb.2024.07.025_bib15","first-page":"184","article-title":"Thyroid hormone receptors: multiple forms, multiple possibilities","volume":"14","author":"Lazar","year":"1993","journal-title":"Endocr Rev"},{"key":"10.1016\/j.apsb.2024.07.025_bib16","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1210\/mend.15.3.0608","article-title":"Hormone selectivity in thyroid hormone receptors","volume":"15","author":"Wagner","year":"2001","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.apsb.2024.07.025_bib17","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1210\/endo.142.2.7935","article-title":"Cardiac ion channel expression and contractile function in mice with deletion of thyroid hormone receptor alpha or beta","volume":"142","author":"Gloss","year":"2001","journal-title":"Endocrinology"},{"key":"10.1016\/j.apsb.2024.07.025_bib18","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/hep.1840200521","article-title":"Hepatocyte proliferation and gene expression induced by triiodothyronine in\u00a0vivo and in\u00a0vitro","volume":"20","author":"Francavilla","year":"1994","journal-title":"Hepatology"},{"key":"10.1016\/j.apsb.2024.07.025_bib19","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jhep.2010.04.028","article-title":"TR\u03b2 is the critical thyroid hormone receptor isoform in T3-induced proliferation of hepatocytes and pancreatic acinar cells","volume":"53","author":"Kowalik","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.apsb.2024.07.025_bib20","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1007\/s12035-015-9375-z","article-title":"Thyroid hormone potentially benefits multiple sclerosis via facilitating remyelination","volume":"53","author":"Zhang","year":"2016","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.apsb.2024.07.025_bib21","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1006\/abbi.1995.0061","article-title":"Transcriptional regulation of rat hepatic low-density lipoprotein receptor and cholesterol 7\u03b1 hydroxylase by thyroid hormone","volume":"323","author":"Ness","year":"1995","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.apsb.2024.07.025_bib22","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/nrd2830","article-title":"Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes","volume":"8","author":"Baxter","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2024.07.025_bib23","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1172\/JCI60580","article-title":"Thyroid hormone stimulates hepatic lipid catabolism via activation of autophagy","volume":"122","author":"Sinha","year":"2012","journal-title":"J Clin Investig"},{"key":"10.1016\/j.apsb.2024.07.025_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mce.2011.05.009","article-title":"Coordination of mitochondrial biogenesis by thyroid hormone","volume":"342","author":"Weitzel","year":"2011","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.apsb.2024.07.025_bib25","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1089\/thy.2000.10.965","article-title":"The direct tri-iodothyronine mitochondrial pathway: science or mythology?.","volume":"10","author":"Wrutniak","year":"2000","journal-title":"Thyroid"},{"key":"10.1016\/j.apsb.2024.07.025_bib26","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1042\/bj3240289","article-title":"Tissue-specific regulation of medium-chain acyl-CoA dehydrogenase gene by thyroid hormones in the developing rat","volume":"324","author":"Djouadi","year":"1997","journal-title":"Biochem J"},{"key":"10.1016\/j.apsb.2024.07.025_bib27","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1042\/bj20021509","article-title":"Investigation of potential mechanisms regulating protein expression of hepatic pyruvate dehydrogenase kinase isoforms 2 and 4 by fatty acids and thyroid hormone","volume":"369","author":"Holness","year":"2003","journal-title":"Biochem J"},{"key":"10.1016\/j.apsb.2024.07.025_bib28","first-page":"E380","article-title":"T3 stimulates resting metabolism and UCP-2 and UCP-3 mRNA but not nonphosphorylating mitochondrial respiration in mice","volume":"277","author":"Jekabsons","year":"1999","journal-title":"Am J Physiol"},{"key":"10.1016\/j.apsb.2024.07.025_bib29","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1074-5521(98)90168-5","article-title":"A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor","volume":"5","author":"Chiellini","year":"1998","journal-title":"Chem Biol"},{"key":"10.1016\/j.apsb.2024.07.025_bib30","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/324425a0","article-title":"A thyromimetic that decreases plasma cholesterol levels without increasing cardiac activity","volume":"324","author":"Underwood","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2024.07.025_bib31","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1021\/jm00396a008","article-title":"Thyroid hormone analogs. Synthesis of 3\u2032-substituted 3,5-diiodo-L-thyronines and quantitative structure-activity studies of in\u00a0vitro and in\u00a0vivo thyromimetic activities in rat liver and heart","volume":"31","author":"Leeson","year":"1988","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.07.025_bib32","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1021\/jm00122a009","article-title":"Selective thyromimetics. Cardiac-sparing thyroid hormone analogs containing 3\u2032-arylmethyl substituents","volume":"32","author":"Leeson","year":"1989","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.07.025_bib33","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1021\/jm00004a015","article-title":"Synthesis and structure-activity relationships of oxamic acid and acetic acid derivatives related to l-thyronine","volume":"38","author":"Yokoyama","year":"1995","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.07.025_bib34","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1124\/mol.52.3.542","article-title":"Beneficial effects of a novel thyromimetic on lipoprotein metabolism","volume":"52","author":"Taylor","year":"1997","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.apsb.2024.07.025_bib35","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1472-6807-8-8","article-title":"Structural basis of GC-1 selectivity for thyroid hormone receptor isoforms","volume":"8","author":"Bleicher","year":"2008","journal-title":"BMC Struct Biol"},{"key":"10.1016\/j.apsb.2024.07.025_bib36","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1210\/endo.141.9.7681","article-title":"The thyroid hormone receptor-\u03b2-selective agonist GC-1 differentially affects plasma lipids and cardiac activity","volume":"141","author":"Trost","year":"2000","journal-title":"Endocrinology"},{"key":"10.1016\/j.apsb.2024.07.025_bib37","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1517\/14728222.2016.1090429","article-title":"Sobetirome: the past, present and questions about the future","volume":"20","author":"Lammel","year":"2016","journal-title":"Expert Opin Ther Tar"},{"key":"10.1016\/j.apsb.2024.07.025_bib38","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1210\/en.2003-0973","article-title":"Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: selective actions relative to 3,5,3\u2032-triiodo-l-thyronine","volume":"145","author":"Grover","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.apsb.2024.07.025_bib39","first-page":"E1135","article-title":"Spared bone mass in rats treated with thyroid hormone receptor TR\u03b2-selective compound GC-1","volume":"285","author":"Freitas","year":"2003","journal-title":"Am J Physiol"},{"key":"10.1016\/j.apsb.2024.07.025_bib40","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1096\/fj.08-108464","article-title":"Thyroid hormone (T3) and TR\u03b2 agonist GC-1 inhibit\/reverse nonalcoholic fatty liver in rats","volume":"22","author":"Perra","year":"2008","journal-title":"FASEB J"},{"key":"10.1016\/j.apsb.2024.07.025_bib41","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1021\/jm021080f","article-title":"Thyroid receptor ligands. 1. agonist ligands selective for the thyroid receptor \u03b21","volume":"46","author":"Ye","year":"2003","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.07.025_bib42","doi-asserted-by":"crossref","first-page":"10067","DOI":"10.1073\/pnas.1633737100","article-title":"Selective thyroid hormone receptor-\u03b2 activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a)\u00a0with reduced cardiovascular liability","volume":"100","author":"Grover","year":"2003","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.apsb.2024.07.025_bib43","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jsbmb.2008.06.010","article-title":"Anti-obesity, anti-diabetic, and lipid lowering effects of the thyroid receptor \u03b2 subtype selective agonist KB-141","volume":"111","author":"Bryzgalova","year":"2008","journal-title":"J Steroid Biochem"},{"key":"10.1016\/j.apsb.2024.07.025_bib44","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1073\/pnas.0705286104","article-title":"The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans","volume":"105","author":"Berkenstam","year":"2008","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.apsb.2024.07.025_bib45","first-page":"906","article-title":"Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia","volume":"362","author":"Ladenson","year":"2010","journal-title":"Obstet Gynecol Surv"},{"key":"10.1016\/j.apsb.2024.07.025_bib46","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S2213-8587(14)70006-3","article-title":"Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomized, double-blind, placebo-controlled phase 3 study","volume":"2","author":"Sjouke","year":"2014","journal-title":"Lancet Diabetes Endo"},{"key":"10.1016\/j.apsb.2024.07.025_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.112006","article-title":"Design, synthesis and biological evaluation of novel TR\u03b2 selective agonists sustained by ADME-toxicity analysis","volume":"188","author":"Runfola","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2024.07.025_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.dib.2020.105206","article-title":"Collecting data through high throughput in\u00a0vitro early toxicity and off-target liability assays to rapidly identify limitations of novel thyromimetics","volume":"29","author":"Runfola","year":"2020","journal-title":"Data Brief"},{"key":"10.1016\/j.apsb.2024.07.025_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222313105","article-title":"TG68, a novel thyroid hormone receptor-\u03b2 agonist for the treatment of NAFLD","volume":"22","author":"Caddeo","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2024.07.025_bib50","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1089\/thy.1994.4.225","article-title":"The variable clinical phenotype in thyroid hormone resistance syndrome","volume":"4","author":"Beck-Peccoz","year":"1994","journal-title":"Thyroid"},{"key":"10.1016\/j.apsb.2024.07.025_bib51","first-page":"1262","article-title":"Spectrum of transcriptional, dimerization, and dominant negative properties of twenty different mutant thyroid hormone \u03b2-receptors in thyroid hormone resistance syndrome","volume":"8","author":"Collingwood","year":"1994","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.apsb.2024.07.025_bib52","doi-asserted-by":"crossref","first-page":"15358","DOI":"10.1073\/pnas.2136689100","article-title":"Ligand selectivity by seeking hydrophobicity in thyroid hormone receptor","volume":"100","author":"Borngraeber","year":"2003","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.apsb.2024.07.025_bib53","doi-asserted-by":"crossref","first-page":"7193","DOI":"10.1021\/acs.jmedchem.2c00144","article-title":"Discovery of a highly selective and H435R-sensitive thyroid hormone receptor \u03b2 agonist","volume":"65","author":"Li","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.07.025_bib54","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1021\/jm4019299","volume":"57","author":"Kelly","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.07.025_bib55","article-title":"Cell-specific transport and thyroid hormone receptor isoform selectivity account for hepatocyte-targeted thyromimetic action of MGL-3196","volume":"23","author":"Hoenes","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2024.07.025_bib56","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1111\/bph.15427","article-title":"Activation of thyroid hormone receptor-\u03b2 improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis","volume":"178","author":"Kannt","year":"2021","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.apsb.2024.07.025_bib57","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.atherosclerosis.2013.07.056","article-title":"Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-\u03b2 agonist","volume":"230","author":"Taub","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.apsb.2024.07.025_bib58","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2024.07.025_bib59","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.jacc.2022.01.023","article-title":"Resmetirom (MGL-3196) in patients with heterozygous familial hypercholesterolemia","volume":"79","author":"Hovingh","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.apsb.2024.07.025_bib60","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2024.07.025_bib61","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1021\/acs.jmedchem.2c01669","article-title":"Discovery of highly potent and selective thyroid hormone receptor \u03b2 agonists for the treatment of nonalcoholic steatohepatitis","volume":"66","author":"Hu","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.07.025_bib62","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1021\/ja031818y","article-title":"Design, synthesis, and characterization of a series of cytochrome P450 3A-activated prodrugs (hepdirect prodrugs) useful for targeting phosph(on)ate-based drugs to the liver","volume":"126","author":"Erion","year":"2004","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.apsb.2024.07.025_bib63","doi-asserted-by":"crossref","first-page":"7075","DOI":"10.1021\/jm800824d","article-title":"Synthesis and biological evaluation of a series of liver-selective phosphonic acid thyroid hormone receptor agonists and their prodrugs","volume":"51","author":"Boyer","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.07.025_bib64","doi-asserted-by":"crossref","first-page":"15490","DOI":"10.1073\/pnas.0702759104","article-title":"Targeting thyroid hormone receptor-\u03b2 agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index","volume":"104","author":"Erion","year":"2007","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.apsb.2024.07.025_bib65","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/hep.22572","article-title":"Reduction of hepatic steatosis in rats and mice after treatment with liver-targeted thyroid hormone receptor agonist","volume":"49","author":"Cable","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.apsb.2024.07.025_bib66","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1089\/thy.2019.0007","article-title":"A liver-specific thyromimetic, VK2809, decreases hepatosteatosis in glycogen storage disease type Ia","volume":"29","author":"Zhou","year":"2019","journal-title":"Thyroid"},{"key":"10.1016\/j.apsb.2024.07.025_bib67","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.jid.2016.03.033","article-title":"The thyroid hormone analogue KB2115 (Eprotirome) prolongs human hair growth (anagen) ex\u00a0vivo","volume":"136","author":"Olah","year":"2016","journal-title":"J Investig Dermatol"},{"key":"10.1016\/j.apsb.2024.07.025_bib68","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.atherosclerosis.2014.09.035","article-title":"The thyroid receptor \u03b2 modulator GC-1 reduces atherosclerosis in ApoE-deficient mice","volume":"237","author":"Kannisto","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.apsb.2024.07.025_bib69","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1210\/en.2005-1561","article-title":"The thyroid hormone receptor-\u03b2 agonist GC-1 induces cell proliferation in rat liver and pancreas","volume":"147","author":"Columbano","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.apsb.2024.07.025_bib70","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1096\/fj.00-0416com","article-title":"Cyclin D1 is an early target in hepatocyte proliferation induced by thyroid hormone (T3)","volume":"15","author":"Pibiri","year":"2001","journal-title":"FASEB J"},{"key":"10.1016\/j.apsb.2024.07.025_bib71","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1002\/hep.26775","article-title":"Tri-iodothyronine induces hepatocyte proliferation by protein kinase A-dependent \u03b2-catenin activation in rodents","volume":"59","author":"Fanti","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.apsb.2024.07.025_bib72","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3727\/105221616X691631","article-title":"Thyroid hormone receptor \u03b2 agonist induces \u03b2-catenin-dependent hepatocyte proliferation in mice: implications in hepatic regeneration","volume":"17","author":"Alvarado","year":"2016","journal-title":"Gene Expr"},{"key":"10.1016\/j.apsb.2024.07.025_bib73","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3727\/105221617X695438","article-title":"The thyromimetic KB2115 (Eprotirome) induces rat hepatocyte proliferation","volume":"17","author":"Szydlowska","year":"2017","journal-title":"Gene Expr"},{"key":"10.1016\/j.apsb.2024.07.025_bib74","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12808","article-title":"Potential role of two novel agonists of thyroid hormone receptor-\u03b2 on liver regeneration","volume":"53","author":"Perra","year":"2020","journal-title":"Cell Prolif"},{"key":"10.1016\/j.apsb.2024.07.025_bib75","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1172\/JCI200112584","article-title":"Thyroid hormone-sympathetic interaction and adaptive thermogenesis are thyroid hormone receptor isoform-specific","volume":"108","author":"Ribeiro","year":"2001","journal-title":"J Clin Investig"},{"key":"10.1016\/j.apsb.2024.07.025_bib76","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1210\/en.2009-0667","article-title":"Expression of uncoupling protein 1 in mouse brown adipose tissue is thyroid hormone receptor-\u03b2 isoform-specific and required for adaptive thermogenesis","volume":"151","author":"Ribeiro","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.apsb.2024.07.025_bib77","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.tem.2004.03.008","article-title":"Selective activation of thyroid hormone signaling pathways by GC-1: a new approach to controlling cholesterol and body weight","volume":"15","author":"Baxter","year":"2004","journal-title":"Trends Endocr Met"},{"key":"10.1016\/j.apsb.2024.07.025_bib78","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1677\/joe.1.07066","article-title":"Thyroid hormone receptor \u03b2-specific agonist GC-1 increases energy expenditure and prevents fat-mass accumulation in rats","volume":"193","author":"Villicev","year":"2007","journal-title":"J Endocrinol"},{"key":"10.1016\/j.apsb.2024.07.025_bib79","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s12072-015-9679-0","article-title":"Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis","volume":"10","author":"Mohamad","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.apsb.2024.07.025_bib80","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1093\/carcin\/20.12.2299","article-title":"Cell proliferation induced by 3,3\u2032,5-triiodo-l-thyronine is associated with a reduction in the number of preneoplastic hepatic lesions","volume":"20","author":"Ledda-Columbano","year":"1999","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.apsb.2024.07.025_bib81","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.semcancer.2010.12.010","article-title":"Beta-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad","volume":"21","author":"Nejak-Bowen","year":"2011","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.apsb.2024.07.025_bib82","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/01926230390173851","article-title":"Effects of the liver mitogens triiodo-thyronine and ciprofibrate on the development of rat hepatocellular carcinoma","volume":"31","author":"Ledda-Columbano","year":"2003","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.apsb.2024.07.025_bib83","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/hep.22750","article-title":"Thyroid hormone receptor ligands induce regression of rat preneoplastic liver lesions causing their reversion to a differentiated phenotype","volume":"49","author":"Perra","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.apsb.2024.07.025_bib84","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1127517","article-title":"Potential use of TG68\u2012a novel thyromimetic\u2012for the treatment of non-alcoholic fatty liver (NAFLD)-associated hepatocarcinogenesis","volume":"13","author":"Caddeo","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.apsb.2024.07.025_bib85","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1210\/en.2016-1842","article-title":"A thyroid hormone-based strategy for correcting the biochemical abnormality in X-linked adrenoleukodystrophy","volume":"158","author":"Hartley","year":"2017","journal-title":"Endocrinology"},{"key":"10.1016\/j.apsb.2024.07.025_bib86","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jsbmb.2009.04.006","article-title":"Induction of the adrenoleukodystrophy-related gene (ABCD2) by thyromimetics","volume":"116","author":"Genin","year":"2009","journal-title":"J Steroid Biochem"},{"key":"10.1016\/j.apsb.2024.07.025_bib87","doi-asserted-by":"crossref","first-page":"5842","DOI":"10.1016\/j.bmc.2016.09.038","article-title":"Sobetirome prodrug esters with enhanced blood\u2012brain barrier permeability","volume":"24","author":"Placzek","year":"2016","journal-title":"Bioorganic Med Chem"},{"key":"10.1016\/j.apsb.2024.07.025_bib88","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1016\/j.bmc.2017.03.047","article-title":"Ester-to-amide rearrangement of ethanolamine-derived prodrugs of sobetirome with increased blood\u2012brain barrier penetration","volume":"25","author":"Ferrara","year":"2017","journal-title":"Bioorganic Med Chem"},{"key":"10.1016\/j.apsb.2024.07.025_bib89","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1089\/thy.2018.0008","article-title":"Sobetirome and its amide prodrug Sob-AM2 exert thyromimetic actions in mct8-deficient brain","volume":"28","author":"Barez-Lopez","year":"2018","journal-title":"Thyroid"},{"key":"10.1016\/j.apsb.2024.07.025_bib90","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1021\/acschemneuro.7b00239","article-title":"Targeting fatty-acid amide hydrolase with prodrugs for CNS-selective therapy","volume":"8","author":"Meinig","year":"2017","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.apsb.2024.07.025_bib91","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3389\/fmed.2020.00331","article-title":"Selective Thyroid hormone receptor-beta (TR\u03b2) agonists: new perspectives for the treatment of metabolic and neurodegenerative disorders","volume":"7","author":"Saponaro","year":"2020","journal-title":"Front Med"},{"key":"10.1016\/j.apsb.2024.07.025_bib92","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.3390\/ijms24076373","article-title":"Mechanisms of demyelination and remyelination strategies for multiple sclerosis","volume":"24","author":"Zhao","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2024.07.025_bib93","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.3390\/ph16091207","article-title":"Synthetic thyroid hormone receptor-beta agonists promote oligodendrocyte precursor cell differentiation in the presence of inflammatory challenges","volume":"16","author":"Baldassarro","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.apsb.2024.07.025_bib94","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/nm.4447","article-title":"Thyroid hormone inhibits lung fibrosis in mice by improving epithelial mitochondrial function","volume":"24","author":"Yu","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2024.07.025_bib95","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.587518","article-title":"Physiological role and use of thyroid hormone metabolites\u2012potential utility in COVID-19 patients","volume":"12","author":"Fr\u00f6hlich","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.apsb.2024.07.025_bib96","first-page":"E89","article-title":"Thyroid hormone receptor-\u03b2 agonists prevent hepatic steatosis in fat-fed rats but impair insulin sensitivity via discrete pathways","volume":"305","author":"Vatner","year":"2013","journal-title":"Am J Physiol"},{"key":"10.1016\/j.apsb.2024.07.025_bib97","doi-asserted-by":"crossref","first-page":"e0122987\/1","DOI":"10.1371\/journal.pone.0122987","article-title":"The amelioration of hepatic steatosis by thyroid hormone receptor agonists is insufficient to restore insulin sensitivity in ob\/ob mice","volume":"10","author":"Martagon","year":"2015","journal-title":"PLoS One"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383524003150?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383524003150?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T22:04:52Z","timestamp":1739916292000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383524003150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":97,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2211383524003150"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2024.07.025","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug discovery targeting thyroid hormone receptor \u03b2 (THR\u03b2) for the treatment of liver diseases and other medical indications","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2024.07.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}